EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 156 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... July 6, 2023 Do as I say, not as I do – when the... July 13, 2021 Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has... April 17, 2019 Load more HOT NEWS AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour What to Know About Navigating Your Cancer Care During An Extreme... EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in...
